Menu
Search
|

Menu

Close
X

Interpace Diagnostics Group Inc IDXG.OQ (NASDAQ Stock Exchange Capital Market)

1.05 USD
+0.00 (+0.00%)
As of 2:29 AM IST
chart
Previous Close 1.05
Open 1.07
Volume 101,840
3m Avg Volume 111,015
Today’s High 1.07
Today’s Low 1.00
52 Week High 4.45
52 Week Low 0.72
Shares Outstanding (mil) 22.16
Market Capitalization (mil) 35.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
12
FY16
13
FY15
43
EPS (USD)
FY17
-0.377
FY16
-4.754
FY15
-12.844
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
24.60
Price to Sales (TTM)
vs sector
2.61
53.63
Price to Book (MRQ)
vs sector
0.90
2.69
Price to Cash Flow (TTM)
vs sector
--
16.86
Total Debt to Equity (MRQ)
vs sector
0.00
96.75
LT Debt to Equity (MRQ)
vs sector
0.00
74.62
Return on Investment (TTM)
vs sector
-13.70
7.23
Return on Equity (TTM)
vs sector
-24.97
12.43

EXECUTIVE LEADERSHIP

Stephen Sullivan
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Jack Stover
President, Chief Executive Officer, Director, Since 2016
Salary: $8,065.00
Bonus: --
James Early
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Since 2016
Salary: $116,519.00
Bonus: --
Felice Schnoll-Sussman
Director, Since 2017
Salary: --
Bonus: --
Joseph Keegan
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Industrials
Industry: Business Support Services
Address:

Morris Corporate Center 1
, Building C, 300 Interpace Park
PARSIPPANY   NJ   07054

Phone: +1412.2246100

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

SPONSORED STORIES